{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T16:11:50Z","timestamp":1779120710250,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1153493"],"award-info":[{"award-number":["APP1153493"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1157643"],"award-info":[{"award-number":["APP1157643"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2007920"],"award-info":[{"award-number":["APP2007920"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007224","name":"National Foundation for Science and Technology Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007224","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001774","name":"The University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s40262-026-01626-4","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:47:32Z","timestamp":1773773252000},"page":"719-730","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Single Saliva Sample Linezolid Dosing for Multidrug-Resistant Tuberculosis: A Population Pharmacokinetic Modelling of Plasma and Saliva"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8508-8990","authenticated-orcid":false,"given":"Thi A.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5531-0223","authenticated-orcid":false,"given":"Tri P.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anh T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luong V.","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoa B.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-6716","authenticated-orcid":false,"given":"Hoa D.","family":"Vu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tram N. B.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dang","family":"Vu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4085-1411","authenticated-orcid":false,"given":"Greg J.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0288","authenticated-orcid":false,"given":"Jan-Willem C.","family":"Alffenaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2114-587X","authenticated-orcid":false,"given":"Sophie L.","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"1626_CR1","unstructured":"WHO. Global Tuberculosis Report 2024 (Section 1.2) [Internet]. https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2024\/tb-disease-burden\/1-2-tb-mortality."},{"key":"1626_CR2","unstructured":"WHO. Tuberculosis resurges as top infectious disease killer [Internet]. https:\/\/www.who.int\/news\/item\/29-10-2024-tuberculosis-resurges-as-top-infectious-disease-killer."},{"key":"1626_CR3","unstructured":"WHO. WHO consolidated guidelines on tuberculosis: module 4: treatment and care, 2025 [Internet]. https:\/\/www.who.int\/publications\/i\/item\/9789240063129."},{"key":"1626_CR4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","volume":"392","author":"N Ahmad","year":"2018","unstructured":"Ahmad N, Ahuja SD, Akkerman OW, Alffenaar J-WC, Anderson LF, Baghaei P, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392:821\u201334. https:\/\/doi.org\/10.1016\/S0140-6736(18)31644-1.","journal-title":"Lancet"},{"key":"1626_CR5","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","volume":"382","author":"F Conradie","year":"2020","unstructured":"Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020;382:893\u2013902. https:\/\/doi.org\/10.1056\/NEJMoa1901814.","journal-title":"N Engl J Med"},{"key":"1626_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107302","volume":"64","author":"J Kuhlin","year":"2024","unstructured":"Kuhlin J, Davies Forsman L, Osman A, Skagerberg M, Jonsson J, Groenheit R, et al. Increased risk of adverse drug reactions by higher linezolid dose per weight in multidrug-resistant tuberculosis. Int J Antimicrob Agents. 2024;64:107302. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107302.","journal-title":"Int J Antimicrob Agents"},{"key":"1626_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106783","volume":"61","author":"C Lau","year":"2023","unstructured":"Lau C, Marriott D, Bui J, Figtree M, Gould M, Chubaty A, et al. LInezolid monitoring to minimise toxicity (LIMMIT1): a multicentre retrospective review of patients receiving linezolid therapy and the impact of therapeutic drug monitoring. Int J Antimicrob Agents. 2023;61:106783. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106783.","journal-title":"Int J Antimicrob Agents"},{"key":"1626_CR8","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00751-17","volume":"61","author":"S Srivastava","year":"2017","unstructured":"Srivastava S, Magombedze G, Koeuth T, Sherman C, Pasipanodya JG, Raj P, et al. Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis. Antimicrob Agents Chemother. 2017;61:e00751-17. https:\/\/doi.org\/10.1128\/AAC.00751-17.","journal-title":"Antimicrob Agents Chemother"},{"key":"1626_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1032674","volume":"13","author":"H Zhang","year":"2022","unstructured":"Zhang H, He Y, Davies Forsman L, Paues J, Werngren J, Niward K, et al. Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis. Front Pharmacol. 2022;13:1032674. https:\/\/doi.org\/10.3389\/fphar.2022.1032674.","journal-title":"Front Pharmacol"},{"key":"1626_CR10","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.ebiom.2015.10.014","volume":"2","author":"G Maartens","year":"2015","unstructured":"Maartens G, Benson CA. Linezolid for treating tuberculosis: a delicate balancing act. EBioMedicine. 2015;2:1568\u20139. https:\/\/doi.org\/10.1016\/j.ebiom.2015.10.014.","journal-title":"EBioMedicine"},{"key":"1626_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","volume":"44","author":"K Matsumoto","year":"2014","unstructured":"Matsumoto K, Shigemi A, Takeshita A, Watanabe E, Yokoyama Y, Ikawa K, et al. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients. Int J Antimicrob Agents. 2014;44:242\u20137. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.05.010.","journal-title":"Int J Antimicrob Agents"},{"key":"1626_CR12","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s11096-019-00886-4","volume":"41","author":"ML Avent","year":"2019","unstructured":"Avent ML, Rogers BA. Optimising antimicrobial therapy through the use of Bayesian dosing programs. Int J Clin Pharm. 2019;41:1121\u201330. https:\/\/doi.org\/10.1007\/s11096-019-00886-4.","journal-title":"Int J Clin Pharm"},{"key":"1626_CR13","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.ijantimicag.2017.01.017","volume":"49","author":"J Kamp","year":"2017","unstructured":"Kamp J, Bolhuis MS, Tiberi S, Akkerman OW, Centis R, de Lange WC, et al. Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis. Int J Antimicrob Agents. 2017;49:688\u201394. https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.01.017.","journal-title":"Int J Antimicrob Agents"},{"key":"1626_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/FTD.0b013e3181cc6d6f","volume":"32","author":"J-WC Alffenaar","year":"2010","unstructured":"Alffenaar J-WC, Kosterink JGW, van Altena R, van der Werf TS, Uges DRA, Proost JH. Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit. 2010;32:97\u2013101. https:\/\/doi.org\/10.1097\/FTD.0b013e3181cc6d6f.","journal-title":"Ther Drug Monit"},{"key":"1626_CR15","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s40262-024-01398-9","volume":"63","author":"TA Nguyen","year":"2024","unstructured":"Nguyen TA, Chen RH, Hawkins BA, Hibbs DE, Kim HY, Wheate NJ, et al. Can we predict drug excretion into saliva? A systematic review and analysis of physicochemical properties. Clin Pharmacokinet. 2024;63:1067\u201387. https:\/\/doi.org\/10.1007\/s40262-024-01398-9.","journal-title":"Clin Pharmacokinet"},{"key":"1626_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/FTD.0000000000000462","volume":"40","author":"SHJ van den Elsen","year":"2018","unstructured":"van den Elsen SHJ, Oostenbrink LM, Heysell SK, Hira D, Touw DJ, Akkerman OW, et al. Systematic review of salivary versus blood concentrations of antituberculosis drugs and their potential for salivary therapeutic drug monitoring. Ther Drug Monit. 2018;40:17\u201337. https:\/\/doi.org\/10.1097\/FTD.0000000000000462.","journal-title":"Ther Drug Monit"},{"key":"1626_CR17","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40262-024-01346-7","volume":"63","author":"L Davies Forsman","year":"2024","unstructured":"Davies Forsman L, Kim HY, Nguyen TA, Alffenaar J-WC. Salivary therapeutic drug monitoring of antimicrobial therapy: feasible or futile? Clin Pharmacokinet. 2024;63:269\u201378. https:\/\/doi.org\/10.1007\/s40262-024-01346-7.","journal-title":"Clin Pharmacokinet"},{"key":"1626_CR18","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/jac\/dkab075","volume":"76","author":"HY Kim","year":"2021","unstructured":"Kim HY, Ruiter E, Jongedijk EM, Ak HK, Marais BJ, Pk B, et al. Saliva-based linezolid monitoring on a mobile UV spectrophotometer. J Antimicrob Chemother. 2021;76:1786\u201392. https:\/\/doi.org\/10.1093\/jac\/dkab075.","journal-title":"J Antimicrob Chemother"},{"key":"1626_CR19","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/bcp.16278","volume":"91","author":"Y Inoue","year":"2025","unstructured":"Inoue Y, Kashiwagi H, Sato Y, Nashimoto S, Endo T, Takahata M, et al. Clinical research for saliva-based therapeutic drug monitoring of linezolid. Br J Clin Pharmacol. 2025;91:774\u201380. https:\/\/doi.org\/10.1111\/bcp.16278.","journal-title":"Br J Clin Pharmacol"},{"key":"1626_CR20","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1128\/AAC.00558-13","volume":"57","author":"MS Bolhuis","year":"2013","unstructured":"Bolhuis MS, van Altena R, van Hateren K, de Lange WCM, Greijdanus B, Uges DRA, et al. Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2013;57:3676\u201380. https:\/\/doi.org\/10.1128\/AAC.00558-13.","journal-title":"Antimicrob Agents Chemother"},{"key":"1626_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/sscp.70051","volume":"8","author":"TA Nguyen","year":"2025","unstructured":"Nguyen TA, Nath CE, Rosser SPA, Stocker SL, Alffenaar JC. Simultaneous quantification of levofloxacin and linezolid in human plasma and saliva using liquid chromatography quadrupole\u2010orbitrap mass spectrometry. SEPARATION SCIENCE PLUS. 2025;8:e70051. https:\/\/doi.org\/10.1002\/sscp.70051.","journal-title":"SEPARATION SCIENCE PLUS"},{"key":"1626_CR22","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1128\/JCM.01248-17","volume":"55","author":"SHJ van den Elsen","year":"2017","unstructured":"van den Elsen SHJ, van der Laan T, Akkerman OW, van der Zanden AGM, Alffenaar J-WC, van Soolingen D. Membrane filtration is suitable for reliable elimination of Mycobacterium tuberculosis from saliva for therapeutic drug monitoring. J Clin Microbiol. 2017;55:3292\u20133. https:\/\/doi.org\/10.1128\/JCM.01248-17.","journal-title":"J Clin Microbiol"},{"key":"1626_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.talanta.2020.122052","volume":"225","author":"B Seyfinejad","year":"2021","unstructured":"Seyfinejad B, Ozkan SA, Jouyban A. Recent advances in the determination of unbound concentration and plasma protein binding of drugs: analytical methods. Talanta. 2021;225:122052. https:\/\/doi.org\/10.1016\/j.talanta.2020.122052.","journal-title":"Talanta"},{"key":"1626_CR24","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1093\/jac\/dkaf169","volume":"80","author":"H Kawasuji","year":"2025","unstructured":"Kawasuji H, Tsuji Y, Miyaki K, Aoyama T, Kurosaki F, Ezaki M, et al. High feasibility of salivary therapeutic drug monitoring in linezolid, but lower feasibility in tedizolid: a single-dose study in healthy subjects and a monocentric prospective exploratory study in patients who received linezolid. J Antimicrob Chemother. 2025;80:2080\u201391. https:\/\/doi.org\/10.1093\/jac\/dkaf169.","journal-title":"J Antimicrob Chemother"},{"key":"1626_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)\u2014a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75:85\u201394. https:\/\/doi.org\/10.1016\/j.cmpb.2003.11.003.","journal-title":"Comput Methods Programs Biomed"},{"key":"1626_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/psp.2013.24","volume":"2","author":"R Keizer","year":"2013","unstructured":"Keizer R, Karlsson M, Hooker A. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacom & Syst Pharma. 2013;2:1\u20139. https:\/\/doi.org\/10.1038\/psp.2013.24.","journal-title":"CPT Pharmacom & Syst Pharma"},{"key":"1626_CR27","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1111\/bcp.15102","volume":"88","author":"AK Tietjen","year":"2022","unstructured":"Tietjen AK, Kroemer N, Cattaneo D, Baldelli S, Wicha SG. Population pharmacokinetics and target attainment analysis of linezolid in multidrug\u2010resistant tuberculosis patients. Br J Clin Pharmacol. 2022;88:1835\u201344. https:\/\/doi.org\/10.1111\/bcp.15102.","journal-title":"Br J Clin Pharmacol"},{"key":"1626_CR28","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1111\/bcp.15823","volume":"89","author":"A Samb","year":"2023","unstructured":"Samb A, Sinkeler F, Bijleveld YA, Van Kaam A, De Haan TR, Math\u00f4t R. Therapeutic drug monitoring of amikacin in preterm and term neonates with late\u2010onset sepsis. Can saliva samples replace plasma samples? Br J Clin Pharmacol. 2023;89:3195\u2013203. https:\/\/doi.org\/10.1111\/bcp.15823.","journal-title":"Br J Clin Pharmacol"},{"key":"1626_CR29","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/jcph.1445","volume":"59","author":"SG Wicha","year":"2019","unstructured":"Wicha SG, Mundkowski RG, Klock A, Hopt UT, Drewelow B, Kloft C, et al. Is moxifloxacin a treatment option for pancreatic infections? A pharmacometric analysis of serum and pancreatic juice. J Clin Pharmacol. 2019;59:1405\u201314. https:\/\/doi.org\/10.1002\/jcph.1445.","journal-title":"J Clin Pharmacol"},{"key":"1626_CR30","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10928-017-9542-0","volume":"44","author":"A-G Dosne","year":"2017","unstructured":"Dosne A-G, Bergstrand M, Karlsson MO. An automated sampling importance resampling procedure for estimating parameter uncertainty. J Pharmacokinet Pharmacodyn. 2017;44:509\u201320. https:\/\/doi.org\/10.1007\/s10928-017-9542-0.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1626_CR31","unstructured":"Holford N. The visual predictive check\u2014superiority to standard diagnostic (Rorschach) plot. Pamplona, Spain; 2005. www.page-meeting.org\/?abstract=738."},{"key":"1626_CR32","unstructured":"U.S. Food and Drug Administration. Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an abbreviated new drug application [Internet]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioequivalence-studies-pharmacokinetic-endpoints-drugs-submitted-under-abbreviated-new-drug."},{"key":"1626_CR33","unstructured":"European Medicines Agency. Guideline on the investigation of bioequivalence. [Internet]. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf."},{"key":"1626_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106999","volume":"62","author":"D Fage","year":"2023","unstructured":"Fage D, Aalhoul F, Cotton F. Protein binding investigation of first-line and second-line antituberculosis drugs. Int J Antimicrob Agents. 2023;62:106999. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106999.","journal-title":"Int J Antimicrob Agents"},{"key":"1626_CR35","doi-asserted-by":"publisher","first-page":"2200239","DOI":"10.1183\/13993003.00239-2022","volume":"60","author":"The CRyPTIC Consortium","year":"2022","unstructured":"The CRyPTIC Consortium. Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis. Eur Respir J. 2022;60:2200239. https:\/\/doi.org\/10.1183\/13993003.00239-2022.","journal-title":"Eur Respir J"},{"issue":"Suppl 4","key":"1626_CR36","doi-asserted-by":"publisher","first-page":"iv7","DOI":"10.1093\/jac\/dkr072","volume":"66","author":"MS Dryden","year":"2011","unstructured":"Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother. 2011;66(Suppl 4):iv7\u201315. https:\/\/doi.org\/10.1093\/jac\/dkr072.","journal-title":"J Antimicrob Chemother"},{"key":"1626_CR37","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1080\/14787210.2016.1225498","volume":"14","author":"S Wasserman","year":"2016","unstructured":"Wasserman S, Meintjes G, Maartens G. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index. Expert Rev Anti Infect Ther. 2016;14:901\u201315. https:\/\/doi.org\/10.1080\/14787210.2016.1225498.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"1626_CR38","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02164-18","volume":"63","author":"S Wasserman","year":"2019","unstructured":"Wasserman S, Denti P, Brust JCM, Abdelwahab M, Hlungulu S, Wiesner L, et al. Linezolid pharmacokinetics in South African patients with drug-resistant tuberculosis and a high prevalence of HIV coinfection. Antimicrob Agents Chemother. 2019;63:e02164-18. https:\/\/doi.org\/10.1128\/AAC.02164-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1626_CR39","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/jac\/dky096","volume":"73","author":"J Millard","year":"2018","unstructured":"Millard J, Pertinez H, Bonnett L, Hodel EM, Dartois V, Johnson JL, et al. Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation. J Antimicrob Chemother. 2018;73:1755\u201362. https:\/\/doi.org\/10.1093\/jac\/dky096.","journal-title":"J Antimicrob Chemother"},{"key":"1626_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01174-20","volume":"64","author":"WA Alghamdi","year":"2020","unstructured":"Alghamdi WA, Al-Shaer MH, An G, Alsultan A, Kipiani M, Barbakadze K, et al. Population pharmacokinetics of linezolid in tuberculosis patients: dosing regimen simulation and target attainment analysis. Antimicrob Agents Chemother. 2020;64:e01174-20. https:\/\/doi.org\/10.1128\/AAC.01174-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"1626_CR41","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","volume":"11","author":"RM Savic","year":"2009","unstructured":"Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11:558\u201369. https:\/\/doi.org\/10.1208\/s12248-009-9133-0.","journal-title":"AAPS J"},{"key":"1626_CR42","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1208\/s12248-012-9387-9","volume":"14","author":"PL Bonate","year":"2012","unstructured":"Bonate PL, Strougo A, Desai A, Roy M, Yassen A, Van Der Walt JS, et al. Guidelines for the quality control of population pharmacokinetic\u2013pharmacodynamic analyses: an industry perspective. AAPS J. 2012;14:749\u201358. https:\/\/doi.org\/10.1208\/s12248-012-9387-9.","journal-title":"AAPS J"},{"key":"1626_CR43","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01381-21","volume":"65","author":"MT Abdelwahab","year":"2021","unstructured":"Abdelwahab MT, Wasserman S, Brust JCM, Dheda K, Wiesner L, Gandhi NR, et al. Linezolid population pharmacokinetics in South African adults with drug-resistant tuberculosis. Antimicrob Agents Chemother. 2021;65:e01381-21. https:\/\/doi.org\/10.1128\/AAC.01381-21.","journal-title":"Antimicrob Agents Chemother"},{"key":"1626_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106589","volume":"59","author":"W Zhou","year":"2022","unstructured":"Zhou W, Nie W, Wang Q, Shi W, Yang Y, Li Q, et al. Linezolid pharmacokinetics\/pharmacodynamics-based optimal dosing for multidrug-resistant tuberculosis. Int J Antimicrob Agents. 2022;59:106589. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106589.","journal-title":"Int J Antimicrob Agents"},{"key":"1626_CR45","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1128\/AAC.00177-10","volume":"54","author":"F Pea","year":"2010","unstructured":"Pea F, Furlanut M, Cojutti P, Cristini F, Zamparini E, Franceschi L, et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother. 2010;54:4605\u201310. https:\/\/doi.org\/10.1128\/AAC.00177-10.","journal-title":"Antimicrob Agents Chemother"},{"key":"1626_CR46","doi-asserted-by":"publisher","unstructured":"Clarke W. Overview of therapeutic drug monitoring. Clinical challenges in therapeutic drug monitoring [Internet]. Elsevier; 2016 [cited 2025 July 2]. p. 1\u201315. https:\/\/doi.org\/10.1016\/B978-0-12-802025-8.00001-5.","DOI":"10.1016\/B978-0-12-802025-8.00001-5"},{"key":"1626_CR47","doi-asserted-by":"publisher","unstructured":"Capiau S, Alffenaar J-W, Stove CP. Alternative sampling strategies for therapeutic drug monitoring. Clinical challenges in therapeutic drug monitoring [Internet]. Elsevier; 2016 [cited 2025 June 26]. p. 279\u2013336. https:\/\/doi.org\/10.1016\/B978-0-12-802025-8.00013-1.","DOI":"10.1016\/B978-0-12-802025-8.00013-1"},{"key":"1626_CR48","unstructured":"WHO. Implementing the end TB strategy: the essentials, 2022 update [Internet]. https:\/\/www.who.int\/publications\/i\/item\/9789240065093."},{"key":"1626_CR49","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s40262-018-0727-5","volume":"58","author":"PJ Colin","year":"2019","unstructured":"Colin PJ, Allegaert K, Thomson AH, Touw DJ, Dolton M, De Hoog M, et al. Vancomycin PHARMACOKINETICS THROUGHOUT LIFE: RESULTS FROM A POOLED POPULATION ANALYSIS AND EVALUATION OF CURRENT DOSING RECOMMENDATIONS. Clin Pharmacokinet. 2019;58:767\u201380. https:\/\/doi.org\/10.1007\/s40262-018-0727-5.","journal-title":"Clin Pharmacokinet"},{"key":"1626_CR50","unstructured":"Food and Drug Administration (FDA). Highlights of prescribing information (linezolid) [Internet]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/206473s011lbl.pdf."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01626-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01626-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01626-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:50:44Z","timestamp":1779119444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01626-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1626"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01626-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants prior to study enrolment, in accordance with the approved protocol.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The model codes that support the findings of this study are accessible in the Supplementary Materials (Table S7).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code available"}},{"value":"The data supporting this study's findings may be available on request from the principal investigator of the study (J.W. Alffenaar).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Ethical approval was granted by the University of Sydney, Australia (Protocol No. 2021\/082, dated 21.10.2021) and the National Lung Hospital, Vietnam (Approval No. 25\/21\/CN-HDDD, dated 27\/04\/2021).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"T.A. Nguyen conceptualised the study, performed drug concentration analysis, performed the pharmacometrics data analyses and wrote the manuscript. T.P. Nguyen provided support for the pharmacometrics data analyses and revised the manuscript. A.T. Nguyen, L.V. Dinh , B.H. Nguyen, D.H. Vu, T.N.B. Nguyen, And D. Vu revised the manuscript. G.J. Fox conceptualised the study and revised the manuscript. J.W. Alffenaar conceptualised the study, supervised the analysis and revised the manuscript. S.L. Stocker conceptualised the study, supervised the analysis and revised the manuscript. All authors revised the manuscript and accepted submission to the journal.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s contributions"}},{"value":"Jan-Willem C. Alffenaar and Sophie L. Stocker are Editorial Board members of\n                      Clinical Pharmacokinetics\n                      . They were not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}